Psilocybin + Psychotherapy for Fibromyalgia
Trial Summary
What is the purpose of this trial?
The pressing need for effective fibromyalgia (FM) treatments, the known safety of psilocybin therapy, and the mechanistic plausibility for potential benefit provide a backdrop for investigating psilocybin therapy as a treatment for FM. The primary objective of this study is to evaluate the clinical benefit of oral psilocybin in concert with psychotherapy to treat chronic pain symptoms in patients with FM.
Do I need to stop my current medications to join the trial?
Yes, you will need to stop taking certain medications. Participants cannot take psychoactive prescription medications regularly, including antidepressants, opioids, and medications with a primary centrally-acting serotonergic effect. If you are on such medications, you may need to taper off with your doctor's support before joining the trial.
What data supports the effectiveness of the treatment Psilocybin + Psychotherapy for Fibromyalgia?
There is no direct data on Psilocybin + Psychotherapy for fibromyalgia, but studies on similar treatments suggest potential benefits. For example, medicinal plants and natural products have shown significant improvements in pain, depression, and quality of life for fibromyalgia patients, indicating that alternative therapies might be effective.12345
Is psilocybin with psychotherapy safe for humans?
How does the drug TRP-8802 (Psilocybin) differ from other treatments for fibromyalgia?
Research Team
Kevin F Boehnke, PhD
Principal Investigator
University of Michigan
Eligibility Criteria
Adults aged 25-64 with fibromyalgia for at least 3 months, stable in psychotherapy, non-smokers, and not using certain medications can join. They must avoid psychoactive substances before sessions and women of childbearing potential need effective birth control.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive two doses of psilocybin: a 15 mg dose followed 2 weeks later by a 25 mg dose, in concert with psychotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Psychotherapy (Behavioral)
- TRP-8802 (Psychedelic)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Kevin Boehnke
Lead Sponsor
TRYP Therapeutics
Lead Sponsor